Financial Results (Q2FY22)—QoQ comparison.

Gland Pharma has reported a total income of Rs. 1131.666 crore during the period ended September 30, 2021, as compared to Rs. 1215.738 crore during the period ended June 30, 2021.

The company has posted a net profit of Rs. 302.081 crore for the period ended September 30, 2021, as against a net profit of Rs. 350.652 crores for the period ended June 30, 2021.

Financial Results (Q2FY22)—YoY comparison

The company has reported a total income of Rs. 1131.666 crores during the period ended September 30, 2021, as compared to Rs.851.852 crores during the period ended September 30, 2020.

 The company has posted a net profit of Rs.302.081 crores for the period ended September 30, 2021, as against a net profit of Rs.218.857 crores for the period ended September 30, 2020.

Financial Results (Half Year Ended FY2022) - YoY comparison

The company has reported total income of Rs.2347.404 crore during the six months period ended September 30, 2021 as compared to Rs.1768.141 crores during the six months period ended September 30, 2020.

The company has posted net profit of Rs.652.733 crores for the six months period ended September 30, 2021 as against net profit of Rs.532.447 crores for the six months period ended September 30, 2020.

Commenting on the results Srinivas Sadu, MD and CEO, Gland Pharma said, ``We continue to focus on revenue diversification across geographies, which is helping us further improve our manufacturing efficiencies because of benefits from scale as well as de-risking the business. With declining Covid-19 hospitalisations, we observed a shift in product mix,"

''Our wide therapeutic portfolio helped us to sustain growth despite changing market demand. Our rich R&D pipeline is helping us maintain strong momentum of new product launches. We are on track to make four complex injectable filings in this financial year," he further added.